In a press conference at SABCS 2014, Prof Rakovitch discusses the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) as a predictor of risk of disease recurrence for patients with ductal carcinoma in situ (DCIS).

DCIS Score may be a good predictor of whether a patient with DCIS who was treated with breast-conserving surgery alone would experience recurrence of DCIS or invasive breast cancer in the same breast.

Read the news story here or watch the interview here.